AG-321

N/A

Report date: 2026/05/13 20:02:10
NME

Base Information

Drug NameAG-321
Drug Alias NamePDGFR-beta, VEGFR-2, tubulin and EGFR inhibitor (Duquesne University/University of Oklahoma/National Cancer Institute)AG-321
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPlatelet-derived growth factor receptor beta inhibitorsTubulin inhibitorsEpidermal growth factor receptor erbB1 inhibitors +[4] 
TargetsPlatelet-derived growth factor receptor betaVascular endothelial growth factor receptor 2Tubulin +[4] 
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesDuquesne University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of Oklahoma Health Sciences CenterDuquesne UniversityNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A